Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has gained second milestone payment from Boehringer Ingelheim under a technology license agreement.
Subscribe to our email newsletter
The amount of the milestone payment and the oncology drug target have not been disclosed.
The payment was generated due to a regulatory submission to commence Phase I trials of a monoclonal antibody that was optimized using Xencor’s XmAb antibody engineering technology.
The companies signed an agreement in 2007 to use Xencor’s proprietary XmAb antibody-dependent cell cytotoxicity technology to boost the potency of therapeutic antibodies.
Xencor CEO Bassil Dahiyat said the clinical pipeline of antibodies with its Fc engineering technology continues to grow, and the company now has six programs being developed in the clinic that employ its technology.
"Our XmAb technology provides key differentiating features such as heightened potency and convenient dosing for both novel antibodies and biosuperiors," Dahiyat added.